Literature DB >> 24658905

New insight into reactive ductular cells of biliary atresia provided by pathological assessment of SOX9.

Hiroko Suda, Daiki Yoshii, Kenichi Yamamura, Yuji Yokouchi, Yukihiro Inomata.   

Abstract

BACKGROUND: Biliary atresia (BA) patients may survive until adolescence after effective Kasai procedure (KP). If liver fibrosis progresses even after successful KP, liver transplantation (LTx) is inevitable. Elucidation of its cause and pathophysiology would open the possibility of treating these patients by non-invasive management. SOX9 is a transcription factor that regulates bile duct development and contributes to liver regeneration and fibrosis. To elucidate the role of SOX9 in BA liver, we investigated the SOX9 expression pattern.
METHOD: Immunostaining with anti-SOX9 antibody was done on hepatic specimens obtained at the time of KP or LTx. We analyzed the association of SOX9 expression with clinical data.
RESULTS: In BA livers, SOX9 was expressed in reactive ductular cells (RDCs), mostly with a nuclear-dominant pattern. SOX9 was also ectopically expressed in hepatocytes, which was more conspicuous at the timing of KP than LTx. SOX9 expression level was significantly correlated with age (days) at which KP was performed, AST and WBC count.
CONCLUSIONS: SOX9 may contribute to RDC formation in BA patients, by affecting both RDCs and hepatocytes. SOX9 could be a key molecule to understand the mechanism of RDC formation, and this understanding would provide a therapeutic strategy for effective treatment of BA.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24658905     DOI: 10.1007/s00383-014-3497-7

Source DB:  PubMed          Journal:  Pediatr Surg Int        ISSN: 0179-0358            Impact factor:   1.827


  33 in total

1.  Cytoplasmic retention of the sex-determining factor SOX9 via the microtubule network.

Authors:  Safia Malki; Philippe Berta; Francis Poulat; Brigitte Boizet-Bonhoure
Journal:  Exp Cell Res       Date:  2005-10-01       Impact factor: 3.905

2.  Identification of hepatocytic and bile ductular cell lineages and candidate stem cells in bipolar ductular reactions in cirrhotic human liver.

Authors:  Hongchao Zhou; Leslie E Rogler; Lewis Teperman; Glyn Morgan; Charles E Rogler
Journal:  Hepatology       Date:  2007-03       Impact factor: 17.425

Review 3.  Ductal plates in hepatic ductular reactions. Hypothesis and implications. I. Types of ductular reaction reconsidered.

Authors:  Valeer J Desmet
Journal:  Virchows Arch       Date:  2011-02-02       Impact factor: 4.064

4.  Sox9 directs hypertrophic maturation and blocks osteoblast differentiation of growth plate chondrocytes.

Authors:  Peter Dy; Weihuan Wang; Pallavi Bhattaram; Qiuqing Wang; Lai Wang; R Tracy Ballock; Véronique Lefebvre
Journal:  Dev Cell       Date:  2012-03-13       Impact factor: 12.270

5.  Epiplakin1 is expressed in the cholangiocyte lineage cells in normal liver and adult progenitor cells in injured liver.

Authors:  Akira Matsuo; Tetsu Yoshida; Takanori Yasukawa; Rika Miki; Kazuhiko Kume; Shoen Kume
Journal:  Gene Expr Patterns       Date:  2011-01-07       Impact factor: 1.224

6.  Intrahepatic bile ducts develop according to a new mode of tubulogenesis regulated by the transcription factor SOX9.

Authors:  Aline Antoniou; Peggy Raynaud; Sabine Cordi; Yiwei Zong; François Tronche; Ben Z Stanger; Patrick Jacquemin; Christophe E Pierreux; Frederic Clotman; Frederic P Lemaigre
Journal:  Gastroenterology       Date:  2009-02-21       Impact factor: 22.682

Review 7.  Biliary atresia.

Authors:  Jane L Hartley; Mark Davenport; Deirdre A Kelly
Journal:  Lancet       Date:  2009-11-14       Impact factor: 79.321

8.  Autosomal sex reversal and campomelic dysplasia are caused by mutations in and around the SRY-related gene SOX9.

Authors:  T Wagner; J Wirth; J Meyer; B Zabel; M Held; J Zimmer; J Pasantes; F D Bricarelli; J Keutel; E Hustert; U Wolf; N Tommerup; W Schempp; G Scherer
Journal:  Cell       Date:  1994-12-16       Impact factor: 41.582

9.  Novel SOX9 expression during human pancreas development correlates to abnormalities in Campomelic dysplasia.

Authors:  K Piper; S G Ball; J W Keeling; S Mansoor; D I Wilson; N A Hanley
Journal:  Mech Dev       Date:  2002-08       Impact factor: 1.882

10.  Sox9b is a key regulator of pancreaticobiliary ductal system development.

Authors:  Marion Delous; Chunyue Yin; Donghun Shin; Nikolay Ninov; Juliana Debrito Carten; Luyuan Pan; Taylur P Ma; Steven A Farber; Cecilia B Moens; Didier Y R Stainier
Journal:  PLoS Genet       Date:  2012-06-14       Impact factor: 5.917

View more
  5 in total

1.  Analysis of soluble factors in conditioned media derived from primary cultures of cirrhotic liver of biliary atresia.

Authors:  Taisuke Yamazaki; Mariko Wakai; Shin Enosawa; Takayoshi Tokiwa
Journal:  In Vitro Cell Dev Biol Anim       Date:  2017-03-31       Impact factor: 2.416

2.  SOX9 contributes to the progression of ductular reaction for the protection from chronic liver injury.

Authors:  Daiki Yoshii; Keita Shimata; Yuji Yokouchi; Yoshihiro Komohara; Hiroko Suda; Masaki Honda; Kenichi Yamamura; Taizo Hibi; Yukihiro Inomata
Journal:  Hum Cell       Date:  2022-02-12       Impact factor: 4.174

3.  Surgical outcome and etiologic heterogeneity of infants with biliary atresia who received Kasai operation less than 60 days after birth: A retrospective study.

Authors:  Zai Song; Rui Dong; Zhen Shen; Gong Chen; Yifan Yang; Shan Zheng
Journal:  Medicine (Baltimore)       Date:  2017-06       Impact factor: 1.889

4.  Characteristics of SOX9-positive progenitor-like cells during cholestatic liver regeneration in biliary atresia.

Authors:  Yuting Lin; Fang Zhang; Ludi Zhang; Lian Chen; Shan Zheng
Journal:  Stem Cell Res Ther       Date:  2022-03-21       Impact factor: 6.832

5.  Differences of core genes in liver fibrosis and hepatocellular carcinoma: Evidence from integrated bioinformatics and immunohistochemical analysis.

Authors:  Yue Li; Shou-Li Yuan; Jing-Ya Yin; Kun Yang; Xin-Gang Zhou; Wen Xie; Qi Wang
Journal:  World J Gastrointest Oncol       Date:  2022-07-15
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.